Results of a new study indicate that aspirin is a safe and effective treatment option for acute migraine. In this prospective, randomized, double-blind, placebo-controlled trial the researchers assessed the efficacy of a 1000mg single dose of aspirin versus placebo in the treatment of acute migraine with or without aura.
Total 401 migraine (confirmed diagnosis) patients are enrolled in this study. Among them 200 received placebo whereas 201 are treated with aspirin. The study participants are instructed to record their responses in a diary at baseline and at .5, 1, 2, 3, 4, 5, 6 and 24 hours after taking the aspirin. A 4-point ordinal scale is used to assess the severity of pain.
The efficacy of aspirin is measured in the terms of headache response at 2 hours after taking the medication. Some other efficacy measures such as reduction in nausea, photophobia and phonophobia, pain intensity difference and headache recurrence at 24 hours are also used to further assess the efficacy of aspirin dosage.
Study results revealed that at 2 hours, 20% of the subjects treated with aspirin were pain free versus only 6% of subjects treated with placebo. Besides this, aspirin group also recorded greater reductions in nausea, photophobia and phonophobia.
The researchers concluded that aspirin is a rational over-the-counter alternative for patients who have migraine